The Venture Codex

Participated · Series A · Mar 2026

NexCure is a Boston-based healthcare startup that aims to remove geographic, financial, and logistical barriers to life-saving cell and gene therapies. The company is building purpose-built outpatient clinics coupled with a proprietary platform that standardizes protocols, automates care coordination, and integrates AI-powered patient selection, remote monitoring, and operational intelligence. By translating hospital-grade clinical rigor into community settings, NexCure seeks to expand access beyond the ~3 % of U.S. hospitals that currently administer CAR-T treatments. Its model is intended to serve patients, referring oncologists, health systems, payers, and manufacturers who need reliable, scalable sites of care. Founded by Raven, RA Capital’s healthcare incubator, the firm is led by an experienced team including former Johns Hopkins Medicine CEO Paul Rothman (Board Chair), CEO Jennifer Smith, CMO Sophie Papa, and CBO Anish More. NexCure has just emerged from stealth with a $19 million Series A round that will fund build-out of its outpatient infrastructure and technology platform. No operating metrics such as revenue or patient volumes have yet been disclosed.

Led · Series A · Jan 2026

RISA Labs develops BOSS Console, an AI-driven operating system that plugs into cancer centers’ EMRs, payer portals and other systems to automate patient access, benefits verification, and prior authorization. Its agent-based software reads, reasons and acts across disparate data sources, adapting in real time to changing payer rules and clinical requirements. Deployed at leading U.S. oncology networks, the platform has freed roughly 80 % of administrative staff time, cut denials by up to 40 %, achieved 97.8 % first-pass approval rates, and reduced authorization turnaround from an 8-day backlog to under 24 hours (with a goal of <2 hours). More than 20 full-time equivalents at one site have been redeployed to higher-value tasks, improving both capacity and financial performance. The company’s immediate roadmap includes expanding AI-driven workflows across the full continuum of cancer care and extending its technology to specialty pharmacy operations. Financially, RISA Labs has secured $11.1 million in Series A funding to accelerate nationwide deployment. Founded by CEO Kshitij Jaggi and CTO Kumar Shivang, the company operates out of Palo Alto, California.

Led · Series B · Mar 2025

Lumata Health provides a human-led, technology-driven care management platform that combines predictive analytics with hundreds of certified ophthalmic care coaches to improve treatment adherence for chronic eye diseases. The platform delivers tailored interventions and partners with physicians, payers, and pharmaceutical manufacturers to enhance clinical outcomes and patient satisfaction. Lumata has partnered with eye care providers across the U.S., including the five largest national and regional eye care networks. The company reports that its proactive model has recently demonstrated up to 800 additional vision-saving eye injections annually for every 1,000 participating patients. Lumata plans to use the new funding to meet growing demand and further enhance the data-driven technology powering its patient adherence solutions. Founded in 2017 and based in Raleigh, N.C., the company has raised $36 million to date. Lumata Health offers an Intelligent Engagement Platform and a human-led continuous care program that combines behavioral information with clinical data to deliver tailored interventions through trained ophthalmic care coaches. The platform was developed with over $2MM in support from the National Eye Institute and is almost always free to patients. Programs are reimbursable under Medicare’s Chronic Care Management billing codes and are covered by secondary, supplement, or Medicare Advantage plans. Clinics using Lumata’s services have reported a 60% reduction in delayed appointments, and the company currently contracts with more than 300,000 patients. Lumata partners with physicians, payers, and health systems to provide between-visit assistance for chronic eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma. New providers can try Lumata for 90 days with no upfront costs or EMR integration required. The company has raised more than $14.8MM in grant and venture funding to date. Lumata Health operates a human-led, intelligent eye care management platform that pairs patients with experienced eye care coordinators and JCAHPO-Certified Ophthalmic Assistants and Technicians to support care between ophthalmologist visits. The platform combines clinical and psychosocial elements with data and technology to improve adherence, education, and to address barriers such as transportation, medication refills, and injection-related anxiety. Lumata currently serves thousands of patients with vision-threatening chronic eye conditions, and data shows patients supported by the platform miss an average of 30% fewer clinic appointments. Its services are almost always free to patients and are reimbursed by most payers, including Medicare and often fully covered with supplemental insurance. The company plans to use new funding to advance predictive analytics, incorporate automated patient communication pathways, and expand offerings like pre-visit intake, prior authorization assistance, and pre-operative cataract education. Lumata was founded in 2017 by ophthalmologist Stephen R. Fransen, MD, and previously received more than $2MM in research funding from the National Eye Institute.

Participated · Series B · May 2024

Atropos Health builds GENEVA OS™, an operating system that converts real-world clinical data into high-quality, personalized real-world evidence and offers vertical user experiences such as ChatRWD™. ChatRWD, launched in beta in Q4 2023, is a chat-based AI co-pilot that the company says cuts production time for publication-grade evidence from months to minutes while aiming to minimize hallucination risk. The platform has been adopted by healthcare institutions, data platforms, research institutions, and life sciences companies. The company positions its products as a trusted quality layer between healthcare data and clinical/research evidence, and aims to democratize access to real-world evidence to improve decision making and patient outcomes. With this funding, Atropos plans to expand its focus on value-based care, deepen vertical integrations (including oncology and specialty care), and scale automation and full launch of ChatRWD. Atropos Health develops GENEVA OS, a Generative Evidence Acceleration Operating System that powers the Atropos Evidence Network and analyzes de-identified medical records. The company says the network includes more than 160 million patients’ de-identified medical data and its new ChatRWD application delivers answers in minutes via natural-language queries and a chat interface. Atropos recently partnered with Google Cloud to optimize GENEVA OS for Google’s healthcare data tools, enabling datasets hosted in Google Cloud to join the Evidence Network seamlessly. The integration is intended to let health systems and pharmaceutical companies generate near-instant insights for use cases such as optimizing formularies, reducing length of stay, accelerating research, and supporting shared decision-making. Atropos emphasizes rigorous data privacy and security measures within Google Cloud’s infrastructure. Financially, the company said it raised an undisclosed strategic financing from Presidio Ventures, Samsung Next, and others to support expansion and its mission to close evidence gaps in medicine worldwide. Atropos Health is a Palo Alto–based developer of a physician consultation service that delivers research-grade real-world evidence at the point of care. The company uses millions of anonymized patient records to help providers answer clinical questions that have fallen through the cracks of the evidence-based literature. Led by newly appointed CEO Brigham Hyde, PhD, Atropos retains President Neil Sanghavi and CMO Dr. Saurabh Gombar, while co-founder Nigam Shah remains on the board. The company will use the $14M Series A to expand its commercial team, build on recent market traction, and continue development of its oncology product. The financing supports continued product development and commercial expansion.

Led · Series A · May 2024

Acclinate is a health equity company focused on increasing diversity in clinical trials. Its core product is a community engagement platform trusted by top pharmaceutical brands to make existing trials more inclusive and to plan more diverse studies. The company also develops the Enhanced Diversity in Clinical Trials (e-DICT) platform and intends to enhance it with new funding. Acclinate raised $7 million in a Series A to scale its impact and expand its initiatives. The funding will support expansion of its community engagement efforts and initiatives aimed at inclusivity and equity in healthcare. The round brings strategic support from established healthcare organizations to help accelerate Acclinate's work. Acclinate Genetics offers a privacy-protecting digital health platform that uses machine learning and predictive analytics to identify and select more diverse clinical-trial and genomic research participants. The company positions its product to decrease the overall cost of drug development, increase the speed of drug approvals, integrate with virtual clinical trials, and contribute to new drug discovery. Co‑founders Del Smith and Tiffany Jordan‑Whitlow started the company after being personally impacted by the lack of minority representation in medicine. Acclinate recently gained backing from Bronze Valley and became the first bio company in that investor's portfolio. The company says it is focused on educating and engaging diverse individuals to make informed decisions about genomic research and clinical trial participation. Acclinate is seeking additional investors and partners as it continues to grow and scale; the clinical trial patient recruitment market is cited at $3.4 billion today and projected to grow to $5.3 billion by 2030.